Adlai Nortye Ltd. American Depositary Shares (ANL) - Total Liabilities
Based on the latest financial reports, Adlai Nortye Ltd. American Depositary Shares (ANL) has total liabilities worth $42.76 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore ANL net asset momentum to track the company's year-over-year net asset growth rate.
Adlai Nortye Ltd. American Depositary Shares - Total Liabilities Trend (2019–2025)
This chart illustrates how Adlai Nortye Ltd. American Depositary Shares's total liabilities have evolved over time, based on quarterly financial data.
Adlai Nortye Ltd. American Depositary Shares Competitors by Total Liabilities
The table below lists competitors of Adlai Nortye Ltd. American Depositary Shares ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Better Collective
ST:BETCO
|
Sweden | Skr440.73 Million |
|
Jilin Forest
SHG:600189
|
China | CN¥2.76 Billion |
|
Clevo Co
TW:2362
|
Taiwan | NT$54.84 Billion |
|
Global Top E Commerce Co Ltd
SHE:002640
|
China | CN¥2.45 Billion |
|
Shanghai Chuangli Group Co Ltd
SHG:603012
|
China | CN¥3.99 Billion |
|
Anteris Technologies Global Corp. Common Stock
NASDAQ:AVR
|
USA | $16.31 Million |
|
Replimune Group Inc
NASDAQ:REPL
|
USA | $123.05 Million |
|
CSBC Corp Taiwan
TW:2208
|
Taiwan | NT$39.28 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down Adlai Nortye Ltd. American Depositary Shares's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Adlai Nortye Ltd. American Depositary Sh (ANL) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.65 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -5.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Adlai Nortye Ltd. American Depositary Shares's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Adlai Nortye Ltd. American Depositary Shares (2019–2025)
The table below shows the annual total liabilities of Adlai Nortye Ltd. American Depositary Shares from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $42.76 Million | -6.62% |
| 2024-12-31 | $45.78 Million | -16.97% |
| 2023-12-31 | $55.14 Million | -82.43% |
| 2022-12-31 | $313.89 Million | -1.02% |
| 2021-12-31 | $317.11 Million | +88.42% |
| 2020-12-31 | $168.30 Million | +109.90% |
| 2019-12-31 | $80.18 Million | -- |
About Adlai Nortye Ltd. American Depositary Shares
Adlai Nortye Ltd., a clinical-stage company, together with its subsidiaries, engages in the research and develops pharmaceutical products. Its product pipeline comprises AN0025, a small molecule EP4 antagonist which is in phase Ib and radiotherapy/chemoradiotherapy combination for the treatment of rectum cancer and esophageal cancer; and phase II trial for patients with moderate to high-risk rect… Read more